TITLE

12th annual North American Cystic Fibrosis Conference. October 15-18, 1998, Montreal, Canada

AUTHOR(S)
Cowley, Elizabeth A.; Cowley, E A
PUB. DATE
February 1999
SOURCE
Clinical & Investigative Medicine;Feb99, Vol. 22 Issue 1, p26
SOURCE TYPE
Academic Journal
DOC. TYPE
research
ABSTRACT
Presents the 12th Annual North American Cystic Fibrosis (CF) Conference in Montreal, Canada, which revealed the latest advances in every aspect of CF disease. Pathogenesis of CF lung disease; Treatment of CF pulmonary disease; Cause of CF.
ACCESSION #
1623159

 

Related Articles

  • Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis. Pedersen, Maya Graham; Jensen-Fangel, Søren; Olesen, Hanne Vebert; Tambe, San deep Prataprao; Petersen, Eskild // BMC Infectious Diseases;Jul2015, Vol. 15 Issue 1, p1 

    Background: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated through a peripheral venous line, PICC-line or PORT-A-CATH (PAC). Methods: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a...

  • Web-Based Intervention for Nutritional Management in Cystic Fibrosis: Development, Usability, and Pilot Trial. Stark, Lori J.; Opipari-Arrigan, Lisa; Filigno, Stephanie S.; Simon, Stacey L.; Leonard, Amanda; Mogayzel, Peter J.; Rausch, Joseph; Zion, Cynthia; Powers, Scott W. // Journal of Pediatric Psychology;Jun2016, Vol. 41 Issue 5, p510 

    Objectives: Usability and pilot testing of a web intervention (BeInCharge.org [BIC]) of behavior plus nutrition intervention for children with cystic fibrosis (CF) ages 4-9 years.Methods: Think Aloud methodology was used with five mothers to assess usability and refine...

  • Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It? Ranganathan, Sarath C.; Hall, Graham L.; Sly, Peter D.; Stick, Stephen M.; Douglas, Tonia A.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF) // American Journal of Respiratory & Critical Care Medicine;6/15/2017, Vol. 195 Issue 12, p1567 

    The past decade has seen significant advances in understanding of the pathogenesis and progression of lung disease in cystic fibrosis (CF). Pulmonary inflammation, infection, and structural lung damage manifest very early in life and are prevalent among preschool children and infants, often in...

  • Viral Vector–mediated and Cell-based Therapies for Treatment of Cystic Fibrosis. Flotte, Terence R.; Ng, Philip; Dylla, Doug E.; McCray, Paul B.; Guoshun Wang; Kolls, Jay K.; Hu, Jim // Molecular Therapy;Feb2007, Vol. 15 Issue 2, p229 

    Gene and cell-based therapies are considered to be potentially powerful new approaches for the management of cystic fibrosis (CF) lung disease. Despite tremendous efforts that have been made, especially in studies to understand the obstacles to gene delivery, major challenges to the application...

  • Gene therapy: the case for cystic fibrosis. Alton, Eric WFW; Geddes, Duncan // Journal of the Royal Society of Medicine (Supplement);Feb1997, Vol. 90 Issue 31, p43 

    The article discusses a study which investigated the use of gene therapy in the treatment of cystic fibrosis. The study suggested that liposome-mediated cystic fibrosis transmembrane conductance regulator gene transfer may be a practical option for initial studies of gene transfer into cystic...

  • Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Stanojevic, Sanja; Davis, Stephanie D.; Retsch-Bogart, George; Webster, Hailey; Davis, Miriam; Johnson, Robin C.; Jensen, Renee; Pizarro, Maria Ester; Kane, Mica; Clem, Charles C.; Schornick, Leah; Subbarao, Padmaja; Ratjen, Felix A. // American Journal of Respiratory & Critical Care Medicine;5/1/2017, Vol. 195 Issue 9, p1216 

    Rationale: Implementation of intervention strategies to prevent lung damage in early cystic fibrosis (CF) requires objective outcome measures that capture and track lung disease.Objectives: To define the utility of the Lung Clearance Index (LCI), measured by multiple...

  • Getting into your genes.  // Hastings Center Report;Mar/Apr93, Vol. 23 Issue 2, p3 

    Describes the three clinical trials of somatic gene therapy for cystic fibrosis (CF) approved by the Recombinant DNA Advisory Committee. Insertion of a normal gene into lung cells; Insertion of the CF gene into nasal epithelial cells.

  • Gene therapy update. C.F. // Science World;12/3/93, Vol. 50 Issue 7, p5 

    Probes on an experimental treatment for cystic fibrosis (CF) called gene therapy. Overview of the techniques used in the therapy; Summary of test results; Safety as a major concern; Different possibilities for complications following gene therapy; Suggestions of the study.

  • Perspectives on Gene Therapy for Cystic Fibrosis Airway Disease. Bigger, B.; Coutelle, C. // BioDrugs;2001, Vol. 15 Issue 9, p615 

    Since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene nearly 12 years ago, cystic fibrosis (CF) has become one of the most intensively investigated monogenetic disorders considered approachable by gene therapy. This has resulted in over 20 clinical trials...

  • Promising new therapies in works for cystic fibrosis. Starr, Cynthia // Drug Topics;8/16/93, Vol. 137 Issue 16, p14 

    Discusses development of therapies for cystic fibrosis (CF). Longer life expectancy; Improvement in life quality; CF as leading, fatal inherited disease in the United States; Explanation of disease's mechanism; Use of antibiotics; Basic molecular and genetic defect in CF; Focus on specific...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics